Medicine in the early twenty-first century: Paradigm and anticipation - EPMA position paper 2016

EPMA Journal

Volumn 7, Issue 1, 2016, Pages

  Golubnitschaja, Olga ^a,b   Baban, Babak ^a,c,d   Boniolo, Giovanni ^a,e,f   Wang, Wei ^a,g,h,i,j   Bubnov, Rostyslav ^a,k,l   Kapalla, Marko ^a   Krapfenbauer, Kurt ^a   Mozaffari, Mahmood S ^a,c,d   Costigliola, Vincenzo ^a,m  

^a European Association for Predictive   (Belgium)

^b UNIVERSITY OF BONN   (Germany)

^c AUGUSTA UNIVERSITY   (United States)

^d MEDICAL COLLEGE OF GEORGIA   (United States)

^e UNIVERSITY OF FERRARA   (Italy)

^f TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^g EDITH COWAN UNIVERSITY   (Australia)

^h CAPITAL MEDICAL UNIVERSITY   (China)

ⁱ WORLD HEALTH ORGANIZATION   (Switzerland)

^j Global Health Epidemiology Reference Group (GHERG)   (United Kingdom)

^k Clinical Hospital Pheophania of State Affairs Department   (Ukraine)

^l ZABOLOTNY INSTITUTE OF MICROBIOLOGY AND VIROLOGY   (Ukraine)

^m European Medical Association   (Belgium)

more..

Author keywords

Advantage; Implementation; Individualised medicine; Limitation; Person centred medicine; Personalised medicine; Precision medicine; Predictive, preventive, and personalised medicine; Stratified medicine; Traditional complementary alternative medicine

Indexed keywords

ALTERNATIVE MEDICINE; BIOBANK; CANCER GENETICS; CANCER SUSCEPTIBILITY; CARDIOVASCULAR DISEASE; CLIENT CENTERED THERAPY; COST EFFECTIVENESS ANALYSIS; DEGENERATIVE DISEASE; ENVIRONMENTAL FACTOR; EPIDEMIC; HUMAN; INFORMATION TECHNOLOGY; MENTAL DISEASE; MOUTH DISEASE; NEUROLOGIC DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; PAIN; PATIENT SELECTION; PERSONALIZED MEDICINE; PREVENTIVE MEDICINE; PRIORITY JOURNAL; PROFESSIONALISM; RARE DISEASE; REGENERATIVE MEDICINE; REVIEW; SPORTS MEDICINE; TOOTH DISEASE; TRANSLATIONAL RESEARCH;

EID: 84992316338     PISSN: 18785077     EISSN: 18785085     Source Type: Journal    
DOI: 10.1186/s13167-016-0072-4     Document Type: Review

References (82)

1. Xue CC. Traditional, complementary and alternative medicine: policy and public health perspectives. Bull World Health Organ. 2008;86(1):77-8. doi: 10.2471/BLT.07.046458.
2. Fokunang CN, Ndikum V, Tabi OY, Jiofack RB, Ngameni B, Guedje NM, Tembe-Fokunang EA, Tomkins P, Barkwan S, Kechia F, Asongalem E, Ngoupayou J, Torimiro NJ, Gonsu KH, Sielinou V, Ngadjui BT, Angwafor 3rd F, Nkongmeneck A, Abena OM, Ngogang J, Asonganyi T, Colizzi V, Lohoue J, Kamsu-Kom. Traditional medicine: past, present and future research and development prospects and integration in the National Health System of Cameroon. Afr J Tradit Complement Altern Med. 2011;8(3):284-95.
3. Wang W, Russell A, Yan Y, Global Health Epidemiology Reference Group (GHERG). Traditional Chinese medicine and new concepts of predictive, preventive and personalized medicine in diagnosis and treatment of suboptimal health. EPMA J. 2014;5(1):4. doi: 10.1186/1878-5085-5-4.
4. Lang CL, Wang MH, Hung KY, Chiang CK, Lu KC. Altered molecular repertoire of immune system by renal dysfunction in the elderly: is prediction and targeted prevention in the horizon? EPMA J. 2013;4(1):17. doi: 10.1186/1878-5085-4-17.
5. Kupaev V, Borisov O, Marutina E, Yan YX, Wang W. Integration of suboptimal health status and endothelial dysfunction as a new aspect for risk evaluation of cardiovascular disease. EPMA J. 2016;7(1):19. doi: 10.1186/s13167-016-0068-0.
6. Golubnitschaja O, Costigliola V, EPMA. EPMA summit 2014 under the auspices of the presidency of Italy in the EU: professional statements. EPMA J. 2015;6(1):4. doi: 10.1186/s13167-015-0026-2.
7. Roberti di Sarsina P, Tassinari M. Person-centred healthcare and medicine paradigm: it's time to clarify. EPMA J. 2015;6(1):11. doi: 10.1186/s13167-015-0033-3.
8. Fischer T, Langanke M, Marschall P, Michl S, editors. Individualized medicine, advances in predictive, preventive and personalised medicine, vol. 7. Springer Dordrecht Heidelberg New York London; 2015. ISBN 978-3-319-11718-8.
9. Realising the potential of stratified medicine. The academy of medical sciences 2013, https://www.acmedsci.ac.uk/viewFile/51e915f9f09fb.pdf (viewed on September 16th 2016)
10. Marino N, Woditschka S, Reed LT, Nakayama J, Mayer M, Wetzel M, Steeg PS. Breast cancer metastasis issue for the personalization of its prevention and treatment. Am J Path. 2013;183(4):1084-95. doi: 10.1016/j.ajpath.
11. Jameson JL, Longo DL. Precision medicine-personalized, problematic, and promising. N Engl J Med. 2015;372(23):2229-34. doi: 10.1056/NEJMsb1503104.
12. Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med. 2015;372(9):793-5. doi: 10.1056/NEJMp1500523.
13. Rubin R. Precision Medicine: The future or simply politics? JAMA. 313(11):1089-91. doi: 10.1001/jama.2015.0957.
14. Patel K. Precision medicine: pros & cons. February 1st 2015. https://kirtipatel.com/2015/02/01/precision-medicine-blessing-or-curse/. Accessed 21 Sept 2016.
15. What are some of the challenges facing precision medicine and the precision medicine initiative? https://ghr.nlm.nih.gov/primer/precisionmedicine/challenges. Accessed 21 Sept 2016.
16. Cardon LR, Harris T. Precision medicine, genomics abd drug discovery. Hum Mol Genet. 2016. doi: 10.1093/hmg/ddw246.
17. Aerts HJWL. The potential of radiomic-based phenotyping in precision medicine: a review. JAMA Oncol. 2016. doi: 10.1001/jamaoncol.2016.2631.
18. Nazha A, Sekeres MA. Precision medicine in myelodysplastic syndromes and leukemias: lessons from sequential mutations. Annu Rev Med. 2016; doi: 10.1146/annurev-med-062915-095637.
19. Precision medicine initiative and data security. May 25th 2016. https://www.whitehouse.gov/blog/2016/05/25/precision-medicine-initiative-and-data-security. Accessed 21 Sept 2016.
20. Andrews RJ, editor. Too big to succeed-profiteering in American medicine. USA: iUniverse; 2013. ISBN: 978-1-14759-7130-9.
21. Andrews RJ, Quintana LM. Unpredictable, unpreventable and impersonal medicine: global disaster response in the 21st century. EPMA J. 2015;6(1):2. doi: 10.1186/s13167-014-0024-9.
22. Golubnitschaja O, editor. Predictive diagnostics and personalized treatment: dream or reality. New York: Nova; 2009. ISBN 978-1-60692-737-3.
23. Cornetta K, Brown CB. Perspective: balancing personalized medicine and personalized care. Acad Med. 2013;88(3):309-13. doi: 10.1097/ACM.0b013e3182806345.
24. Boniolo G, Sanchini V, editors. Ethical counselling and medical decision-making in the era of personalised medicine. A practice-oriented guide. Springer Dordrecht Heidelberg New York London; 2016. ISBN 978-3-319-27690-8.
25. Redig AJ, McAllister SS. Breast cancer as a systemic disease: a view of metastasis. J Intern Med. 2013;274(2):113-26. doi: 10.1111/joim.12084.
26. Cox TR, Rumney RMH, Schoof EM, Perryman L, Høye AM, Agrawal A, Bird D, Latif NA, Forrest H, Evans HR, Huggins ID, Lang G, Linding R, Gartland A, Erler JT. The hypoxic cancer secretome induces pre-metastatic bone lesions through lysyl oxidase. Nature. 2015;522(7554):106-10. doi: 10.1038/nature14492.
27. Golubnitschaja O and Sridhar KC. Liver metastatic disease: new concepts and biomarker panels to improve individual outcomes. Clin Exp Metastasis. 2016; doi: 10.1007/s10585-016-9816-8.
28. Grech G, Zhan X, Yoo BC, Bubnov R, Hagan S, Danesi R, Vittadini G, Desiderio DM. EPMA position paper in cancer: current overview and future perspectives. EPMA J. 2015;6(1):9. doi: 10.1186/s13167-015-0030-6.
29. Golubnitschaja O, Debald M, Yeghiazaryan K, Kuhn W, Pešta M, Costigliola V, Grech G. Breast cancer epidemic in the early 21st century: evaluation of risk factors, cumulative questionnaires and recommendations for preventive measures. Tumor Biol. 2016; doi: 10.1007/s13277-016-5168-x.
30. Brunner-La Rocca HP, Fleischhacker L, Golubnitschaja O, Heemskerk F, Helms T, Hoedemakers T, Allianses SH, Jaarsma T, Kinkorova J, Ramaekers J, Ruff P, Schnur I, Vanoli E, Verdu J, Zippel-Schultz B. Challenges in personalised management of chronic diseases-heart failure as prominent example to advance the care process. EPMA J. 2016;7:2. doi: 10.1186/s13167-016-0051-9.
31. Konieczka K, Ritch R, Traverso CE, Kim DM, Kook MS, Gallino A, Golubnitschaja O, Erb C, Reitsamer HA, Kida T, Kurysheva N, Yao K. Flammer syndrome. EPMA J. 2014;5(1):11. doi: 10.1186/1878-5085-5-11.
32. Golubnitschaja O, Debald M, Kuhn W, Yeghiazaryan K, Bubnov RV, Goncharenko VM, Lushchyk U, Grech G, Konieczka K. Flammer syndrome and potential formation of pre-metastatic niches: a multi-centred study on phenotyping, patient stratification, prediction and potential prevention of aggressive breast cancer and metastatic disease. EPMA J. 2016;7 Suppl 1:A25.
33. Konieczka K, Koch S, Binggeli T, Schoetzau A, Kesselring J. Multiple sclerosis and primary vascular dysregulation (Flammer syndrome). EPMA J. 2016;7:13. doi: 10.1186/s13167-016-0062-6.
34. Iso H. Promoting predictive, preventive and personalized medicine in treatment of cardiovascular diseases. EPMA J. 2011;2(1):1-4. doi: 10.1007/s13167-011-0075-0.
35. Golubnitschaja O, Costigliola V, EPMA. General report & recommendations in predictive, preventive and personalised medicine 2012: white paper of the European association for predictive, preventive and personalised medicine. EPMA J. 2012;3(1):14. doi: 10.1186/1878-5085-3-14.
36. Helms TM, Duong G, Zippel-Schultz B, Tilz RR, Kuck K-H, Karle CA. Prediction and personalised treatment of atrial fibrillation-stroke prevention: consolidated position paper of CVD professionals. EPMA J. 2014;5(1):15. doi: 10.1186/1878-5085-5-15.
37. Mozaffari MS, editor. New strategies to advance pre/diabetes care: integrative approach by PPPM, advances in predictive, preventive and personalised medicine, vol. 2. Springer Dordrecht Heidelberg New York London; 2013. ISBN 978-94-007-5970-1.
38. Golubnitschaja O. Time for new guidelines in advanced diabetes care: paradigm change from delayed interventional approach to predictive, preventive and personalized medicine. EPMA J. 2010;1(1):3-12. doi: 10.1007/s13167-010-0014-5.
39. Golubnitschaja O, Yeghiazaryan K, Cebioglu M, Morelli M, Herrera-Marschitz M. Birth asphyxia as the major complication in newborns: moving towards improved individual outcomes by prediction, targeted prevention and tailored medical care. EPMA J. 2011;2(2):197-210. doi: 10.1007/s13167-011-0087-9.
40. Mandel S, editor. Neurodegenerative diseases: integrative PPPM approach as the medicine of the future, advances in predictive, preventive and personalised medicine, vol. 3. Springer Dordrecht Heidelberg New York London; 2013. ISBN 978-94-007-5865-0.
41. Sinnecker T, Kuchling J, Dusek P, Dörr J, Niendorf T, Paul F, Wuerfel J. Ultrahigh field MRI in clinical neuroimmunology: a potential contribution to improved diagnostics and personalised disease management. EPMA J. 2015;6(1):16. doi: 10.1186/s13167-015-0038-y.
42. Polivka J, Polivka Jr J, Krakorova K, Peterka M, Topolcan O. Current status of biomarker research in neurology. EPMA J. 2016;7:14. doi: 10.1186/s13167-016-0063-5.
43. Özgüç M, editor. Rare diseases-integrative PPPM approach as the medicine of the future, advances in predictive, preventive and personalised medicine, vol. 6. Springer Dordrecht Heidelberg New York London; 2015. ISBN 978-94-017-9213-4.
44. Roberti di Sarsina P, Alivia M, Guadagni P. Traditional, complementary and alternative medical systems and their contribution to personalisation, prediction and prevention in medicine-person-centred medicine. EPMA J. 2012;3(1):15. doi: 10.1186/1878-5085-3-15.
45. Bubnov RV. Evidence-based pain management: is the concept of integrative medicine applicable? EPMA J. 2012;3(1):13. doi: 10.1186/1878-5085-3-13.
46. Arai YC, Yasui H, Isai H, Kawai T, Nishihara M, Sato J, Ikemoto T, Inoue S, Ushida T. The review of innovative integration of Kampo medicine and Western medicine as personalized medicine at the first multidisciplinary pain center in Japan. EPMA J. 2014;5(1):10. doi: 10.1186/1878-5085-5-10.
47. Moiseyenko YV, Sukhorukov VI, Pyshnov GY, Mankovska IM, Rozova KV, Miroshnychenko OA, Kovalevska OE, Madjar SA, Bubnov RV, Gorbach AO, Danylenko KM, Moiseyenko OI. Antarctica challenges the new horizons in predictive, preventive, personalized medicine: preliminary results and attractive hypotheses for multi-disciplinary prospective studies in the Ukrainian "Akademik Vernadsky" station. EPMA J. 2016;7:11. doi: 10.1186/s13167-016-0060-8. Erratum in: EPMA J. 2016;7:17.
48. Cafiero C, Matarasso S. Predictive, preventive, personalised and participatory periodontology: "the 5Ps age" has already started. EPMA J. 2013;4(1):16. doi: 10.1186/1878-5085-4-16.
49. Golubnitschaja O, Costigliola V. Dental health: EPMA recommendations for innovative strategies. EPMA J. 2014;5 Suppl 1:A119.
50. Kunin AA, Evdokimova AY, Moiseeva NS. Age-related differences of tooth enamel morphochemistry in health and dental caries. EPMA J. 2015;6(1):3. doi: 10.1186/s13167-014-0025-8.
51. Tachalov VV, Orekhova LY, Kudryavtseva TV, Isaeva ER, Loboda ES. Manifestations of personal characteristics in individual oral care. EPMA J. 2016;7:8. doi: 10.1186/s13167-016-0058-2.
52. Qin X, Liu JY, Abdelsayed R, Shi X, Yu JC, Mozaffari MS, Baban B. The status of glucocorticoid-induced leucine zipper protein in the salivary glands in Sjögren's syndrome: predictive and prognostic potentials. EPMA J. 2016;7:3. doi: 10.1186/s13167-016-0052-8.
53. Trovato GM. Behavior, nutrition and lifestyle in a comprehensive health and disease paradigm: skills and knowledge for a predictive, preventive and personalized medicine. EPMA J. 2012;3(1):8. doi: 10.1007/s13167-012-0141-2.
54. Shapira N. Women's higher health risks in the obesogenic environment: a gender nutrition approach to metabolic dimorphism with predictive, preventive, and personalised medicine. EPMA J. 2013;4(1):1. doi: 10.1186/1878-5085-4-1.
55. Richter K, Acker J, Adam S, Niklewski G. Prevention of fatigue and insomnia in shift workers-a review of non-pharmacological measures. EPMA J. 2016;7:16. doi: 10.1186/s13167-016-0064-4.
56. Oja P, Titze S. Physical activity recommendations for public health: development and policy context. EPMA J. 2011;2:253-9.
57. Graf C. Preventing and treating obesity in pediatrics through physical activity. EPMA J. 2011;2(3):261-70. doi: 10.1007/s13167-011-0091-0.
58. Schulte S, Rasmussen NN, McBeth JW, Richards PQ, Yochem E, Petron DJ, Strathmann FG. Utilization of the clinical laboratory for the implementation of concussion biomarkers in collegiate football and the necessity of personalized and predictive athlete specific reference intervals. EPMA J. 2016;7:1. doi: 10.1186/s13167-016-0050-x.
59. Trovato FM, Catalano D, Musumeci G, Trovato GM. 4Ps medicine of the fatty liver: the research model of predictive, preventive, personalized and participatory medicine-recommendations for facing obesity, fatty liver and fibrosis epidemics. EPMA J. 2014;5(1):21. doi: 10.1186/1878-5085-5-21.
60. Younesi E, Hofmann-Apitius M. From integrative disease modeling to predictive, preventive, personalized and participatory (P4) medicine. EPMA J. 2013;4:23. doi: 10.1186/1878-5085-4-23.
61. Drucker E, Krapfenbauer K. Pitfalls and limitations in translation from biomarker discovery to clinical utility in predictive and personalised medicine. EPMA J. 2013;4:7. doi: 10.1186/1878-5085-4-7.
62. Hu R, Wang X, Zhan X. Multi-parameter systematic strategies for predictive, preventive and personalised medicine in cancer. EPMA J. 2013;4(1):2. doi: 10.1186/1878-5085-4-2.
63. Lemke HU, Golubnitschaja O. Towards personal health care with model-guided medicine: long-term PPPM-related strategies and realisation opportunities within "Horizon 2020". EPMA J. 2014;5(1):8. doi: 10.1186/1878-5085-5-8.
64. Berliner L, Lemke HU, VanSonnenberg E, Ashamalla H, Mattes MD, Dosik D, Hazin H, Shah S, Mohanty S, Verma S, Esposito G, Bargellini I, Battaglia V, Caramella D, Bartolozzi C, Morrison P. Model-guided therapy for hepatocellular carcinoma: a role for information technology in predictive, preventive and personalized medicine. EPMA J. 2014;5(1):16. doi: 10.1186/1878-5085-5-16.
65. Berliner L, Lemke HU, editors. An information technology framework for predictive, preventive and personalised medicine, a use-case with hepatocellular carcinoma, advances in predictive, preventive and personalised medicine, vol. 8. Springer Dordrecht Heidelberg New York London; 2015. ISBN 978-3-319-12165-9.
66. Kinkorova J. Biobanks in the era of personalized medicine: objectives, challenges, and innovation: overview. EPMA J. 2016;7:4. doi: 10.1186/s13167-016-0053-7.
67. Grech G, Grossman I, editors. Preventive and predictive genetics: towards personalised medicine, advances in predictive, preventive and personalised medicine, vol. 9. Springer Dordrecht Heidelberg New York London; 2015. ISBN 978-3-319-15343-8.
68. Hagan S, Martin E, Enríquez-de-Salamanca A. Tear fluid biomarkers in ocular and systemic disease: potential use for predictive, preventive and personalised medicine. EPMA J. 2016;7:15. doi: 10.1186/s13167-016-0065-3.
69. Girotra S, Yeghiazaryan K, Golubnitschaja O. Potential biomarker panels in overall breast cancer management: advancements by multilevel diagnostics. Pers Med. 2016;13(5):469-84. doi: 10.2217/pme-2016-0020.
70. Waerner T, Thurnher D, Krapfenbauer K. The role of laboratory medicine in healthcare: quality requirements of immunoassays, standardisation and data management in prospective medicine. EPMA J. 2010;1(4):619-26. doi: 10.1007/s13167-010-0053-y.
71. Golubnitschaja O, Watson ID, Topic E, Sandberg S, Ferrari M, Costigliola V. Position paper of the EPMA and EFLM: a global vision of the consolidated promotion of an integrative medical approach to advance health care. EPMA J. 2013;4(1):12. doi: 10.1186/1878-5085-4-12.
72. Costigliola V. Healthcare overview: new perspectives, advances in predictive, preventive and personalised medicine, vol. 1. Springer Dordrecht Heidelberg New York London; 2012. ISBN 978-94-007-4602-2.
73. Gahan PB. Circulating nucleic acids in early diagnosis, prognosis and treatment monitoring, advances in predictive, preventive and personalised medicine, vol. 5. Springer Dordrecht Heidelberg New York London; 2015. ISBN 978-94-017-9167-0.
74. Abraham J-A, Yeghiazaryan K, Golubnitschaja O. Selective internal radiation therapy in treatment of hepatocellular carcinoma: new concepts of personalization. Pers Med. 2016;13(4):347-60. doi: 10.2217/pme-2016-0014.
75. Abraham J-A, Golubnitschaja O. Time for paradigm change in management of hepatocellular carcinoma: is a personalized approach on the horizon? Pers Med. 2016;13(5):455-67. doi: 10.2217/pme-2016-0013.
76. Boniolo G, Di Fiore PP, Pece S. Trusted consent and research biobanks. Towards a "new alliance" between researchers and donors. Bioethics. 2012;26(2):93-100. doi: 10.1111/j.1467-8519.2010.01823.x.
77. Sanchini V, Bonizzi G, Disalvatore D, Monturano M, Pece S, Viale G, Di Fiore PP, Boniolo G. A trust-based pact in research biobanks. From theory to practice. Bioethics. 2016;30(4):260-71. doi: 10.1111/bioe.12184.
78. Golubnitschaja O, Lemke HU, Kapalla M, Kent A. Design in predictive, preventive and personalised medicine. In: Kuksa I, Fisher T, editors. Design for Personalisation. London: Gower Publishing; 2017. in press.
79. Ausweger C, Burgschwaiger E, Kugler A, Schmidbauer R, Steinek I, Todorov Y, Thurnher D, Krapfenbauer K. Economic concerns about global healthcare in lung, head and neck cancer: meeting the economic challenge of predictive, preventive and personalized medicine. EPMA J. 2010;1(4):627-31. doi: 10.1007/s13167-010-0054-x.
80. Brown PM. Personalized medicine and comparative effectiveness research in an era of fixed budgets. EPMA J. 2010;1(4):633-40. doi: 10.1007/s13167-010-0058-6.
81. Golubnitschaja O, Kinkorova J, Costigliola V. Predictive, preventive and personalised medicine as the hardcore of 'Horizon 2020': EPMA position paper. EPMA J. 2014;5(1):6. doi: 10.1186/1878-5085-5-6.
82. Akhmetov I, Bubnov RV. Assessing value of innovative molecular diagnostic tests in the concept of predictive, preventive, and personalized medicine. EPMA J. 2015;6:19. doi: 10.1186/s13167-015-0041-3.